|
What is angiogenesis ?
Tumors cells need a rich blood supply
in order to grow and metastasize. Angiogenesis is the process
by which new blood vessels, called capillaries are formed. Capillaries
are lined with endothelial cells.
¥Vascular endothelial growth factor
receptor (VEGFR) inhibitor targets KDR tyrosine kinase. We demonstrated
that A potent VEGFR tyrosine kinase inhibitor (VEGFR-TKI) also
blocks Flt-1tyrosine kinase, which is another VEGF receptor.
This compound inhibits migration of vascular endothelial cells
in response to placenta growth factor (PlGF). Moreover, this
compound inhibits PlGF-induced angiogenesis in Matrigel plug
assay.
Anti-angiogenic activity of this compound appears to be because
of inhibition of not only KDR but also Flt-1 tyrosine kinase.
¥Epidermal growth factor receptor (EGFR)
tyrosine kinase is a potential target for anticancer therapy.
We demonstrated that the antitumor effects of EGFR tyrosine kinase
inhibitor (EGFR-TKI) could be mediated in part by inhibition
of tumor angiogenesis through direct effects on microvascular
endothelial cells (EGFR-TKI inhibited EGF-induced formation of
tube-like structures ) and also through reduced production of
proangiogenic factors (VEGF, IL-8) by tumor cells.
|